Sign in
4

Changes in Ownership

Kalaris Therapeutics, Inc. Filed Acc 0000899243-22-013339

Chief Accounting Officer acquired 17,442 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Hagen Brett R · Chief Accounting Officer

Table I: Non-derivative

1 line
Date Transaction Shares Owned after D/I
2022-01-18 Grant or award : show line 1 in the form +17,442 80,644 D

Table II: Derivative

1 line
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2022-01-18 Grant or award : show line 2 in the form Stock Option (Right to Buy) +42,558 $9.15 2032-01-18 42,558 42,558 D
Loading xslF345X03/doc4.xml…